Docetaxel Polymeric Nanoparticles

Docetaxel polymeric nanoparticles (PNPs) are nanoparticles composed of tocofersolan (TPGS, Cay-34661), poloxanlene, trehalose (Cay-20517), and TBS that encapsulate docetaxel (Cay-11637) and are 15 to 20 nm in size as determined by dynamic light scattering (DLS). PNP formulations are a lipid-based drug delivery (LBDD) system that improve drug bioavailability and solubility, protect the cargo from degradation or metabolism, control drug release, and help lower the biological impacts observed by DMSO and other organic solvents. Docetaxel is a microtubule-stabilizing agent and a semisynthetic derivative of paclitaxel (Cay-10461). Formulations containing docetaxel have been used in the treatment of head and neck, breast, and non-small cell lung cancer, gastric adenocarcinoma, and castration-resistant prostate cancer. Before use, reconstitute the docetaxel PNPs in 1 ml of deionized water and dilute the reconstituted docetaxel PNPs prior to performing biological experiments.Synonyms: Docetaxel PNPs, Docetaxel Polymer-based Nanoparticles, DTX PNPs, RP 56976 PNPs. Formulation: (Request formulation change), 2 mg of docetaxel contained in TBS-buffered TPGS and poloxanlene polymeric nanoparticles containing trehalose. Storage Buffer: TBS, pH 7.4, when resuspended in 1 ml water.